Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 5, 2010, Pages 667-675

  Gao, Ying ^a   Lu, Na ^a   Ling, Yun ^a   Chen, Yan ^a   Wang, Ling ^a   Zhao, Qing ^a   Qi, Qi ^a   Liu, Wei ^a   Zhang, Haiwei ^a   You, Qidong ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; KDR Flk 1; Oroxylin A; VEGF

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; OROXYLIN A; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; FLAVONOID; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; VASCULOTROPIN A;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ARTICLE; ASSAY; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT AORTIC RING ASSAY; SIGNAL TRANSDUCTION; TRANSWELL ASSAY; TUBE FORMATION ASSAY; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; ONCOGENE PROTEIN V-AKT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950482760     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0705-2     Document Type: Article

References (36)

1. Berger AC, Wang XQ, Zalatoris A et al (2004) A murine model of ex vivo angiogenesis using aortic disks grown in Wbrin clot. Microvasc Res 68:179-187
2. Blagosklonny MV (2004) Antiangiogenic therapy and tumor progression. Cancer Cell 5:13-17
3. Cabebe E, Wakelee H (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 8:15-27
4. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660
5. Carnesecchi S, Bras-Goncalves R, Bradaia A et al (2004) Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-Xuorouracil efficacy on human colon tumor xenografts. Cancer Lett 215:53-59
6. Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277:3101-3108
7. Collins TS, Hurwitz HI (2005) Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 32:61-68
8. Ellis LM, Takahashi Y, Liu W, Shaheen RM (2000) Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 5(suppl 1):11-15
9. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15-18
10. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18
11. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286 (Pubitemid 46505878)
12. Goodwin AM (2007) In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74:172-183
13. Hu Y, Yang Y, You QD et al (2006) Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem Biophys Res Commun 351:521-527
14. Huang C, Jacobson K, Schaller MD (2004) MAP kinases and cell migration. J Cell Sci 117:4619-4628
15. JaVe EA, Nachman RL, Becker CG et al (1973) Culture of human endothelial cells derived from umbilical veins. IdentiWcation by morphologic and immunologic criteria. J Clin Invest 52:2745-2756
16. Jiang BH, Liu LZ (2008) AKT signaling in regulating angiogenesis. Current Cancer Drug Targets 8:19-26
17. Kakeji Y, Koga T, Sumiyoshi Y (2002) Clinical signiWcance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 21:125-129
18. Kanno S, Oda N, Abe M et al (2000) Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF eVects in human vascular endothelial cells. Oncogene 19:2138-2146
19. Kitamura T, Asai N, Enomoto A et al (2008) Regulation of VEGFmediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol 10:329-337
20. Li HB, Chen F (2005) Isolation and puriWcation of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074:107-110
21. Li HN, Nie FF, Liu W et al (2009) Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 257:80-85
22. Ling Y, Yang Y, Lu N et al (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic Effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361:79-84
23. Meyer RD, Rahimi (2003) Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems? Ann N Y Acad Sci 995:200-207
24. Min JK, Han KY, Kim EC et al (2004) Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 64:644-651
25. Nicosia RF, Bonanno E, Villaschi S (1992) Large-vessel endothelium switches to a microvascular phenotype during angiogenesis in collagen gel culture of rat aorta. Atherosclerosis 95:191-199
26. Restucci B, De Vico G, Maiolino P (2000) Evaluation of angiogenesis in canine mammary tumors by quantitative platelet endothelial cell adhesion molecule immunohistochemistry. Vet Pathol 37:297-301
27. Sathornsumetee S, Rich JN (2007) Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 13:3545-3558 (Pubitemid 350238925)
28. Shibuya M (2006a) DiVerential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469-478
29. Shibuya M (2006b) Vascular endothelial growth factor (VEGF)-receptor2: its biological functions, major signaling pathway, and speciWc ligand VEGF-E. Endothelium 13:63-69
30. Sonoda M, Nishiyama T, Matsukawa Y et al (2004) Cytotoxic activities of Xavonoids from two Scutellaria plants in Chinese medicine. J Ethnopharmacol 91:65-68
31. Sun Y, Lu N, Ling Y et al (2009) Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase- 2/9 in MDA-MB-435 human breast cancer cells. Eur J Pharmacol 603:22-28
32. Tian X, Song S, Wu J (2001) Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 286:505-512
33. Vermeulen PB, Gasparini G, Fox SB et al (1996) QuantiWcation of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484
34. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169-180
35. Wu ZQ, Guo QL, You QD et al (2004) Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 27:1769-1774
36. Yang Y, Hu Y, Gu HY et al (2008) Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 60:1459-1463